We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment CALGARY, Alberta, Jan. 18, 2022 (GLOBE...
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients This initiative will...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone CALGARY, Alberta, Nov. 01...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.68 | 1.68 | 1.68 | 2000 | 1.68 | DE |
4 | 0 | 0 | 1.68 | 1.68 | 1.68 | 4130 | 1.68 | DE |
12 | 0 | 0 | 1.68 | 1.68 | 1.68 | 5917 | 1.68 | DE |
26 | 0 | 0 | 1.68 | 1.68 | 1.68 | 3532 | 1.68 | DE |
52 | 0 | 0 | 1.68 | 1.68 | 1.68 | 2324 | 1.68 | DE |
156 | 0 | 0 | 1.68 | 1.68 | 1.68 | 1559 | 1.68 | DE |
260 | 0 | 0 | 1.68 | 1.68 | 1.68 | 932 | 1.68 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions